valproic acid has been researched along with exp3174 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fukami, T; Hosomi, H; Iwamura, A; Nakajima, M; Yokoi, T | 1 |
| Babaoglu, MO; Bilir, E; Bozkurt, A; Gunes, A; Yasar, U; Zengil, H | 1 |
1 trial(s) available for valproic acid and exp3174
| Article | Year |
|---|---|
Inhibitory effect of valproic acid on cytochrome P450 2C9 activity in epilepsy patients.
Topics: Adolescent; Adult; Anticonvulsants; Aryl Hydrocarbon Hydroxylases; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2C9; Drug Antagonism; Epilepsy; Female; Genotype; Humans; Imidazoles; Losartan; Male; Middle Aged; Polymerase Chain Reaction; Tetrazoles; Valproic Acid | 2007 |
1 other study(ies) available for valproic acid and exp3174
| Article | Year |
|---|---|
CYP2C9-mediated metabolic activation of losartan detected by a highly sensitive cell-based screening assay.
Topics: Antihypertensive Agents; Aryl Hydrocarbon Hydroxylases; Benzbromarone; Biotransformation; Cyclooxygenase Inhibitors; Cytochrome P-450 CYP2C9; Diclofenac; HEK293 Cells; Hep G2 Cells; Hepatocytes; Humans; Losartan; NF-E2-Related Factor 2; Semicarbazides; Sensitivity and Specificity; Time Factors; Uricosuric Agents | 2011 |